ACOG (Alpha Cognition) Return-on-Tangible-Equity: -43.47% (As of Mar. 2026)


ACOG Alpha Cognition Inc ACOG
32 GF Score
Price $6.50
! 3 Warning Signs
View Full Analysis

What is Alpha Cognition Return-on-Tangible-Equity?

Alpha Cognition ACOG 32 Return-on-Tangible-Equity is -43.47% as of Mar. 2026. GuruFocus rates ACOG with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,202 Biotechnology companies, Alpha Cognition ranks worse than 57.65% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alpha Cognition's annualized net income for the quarter that ended in Mar. 2026 was $-25.91 Mil. Alpha Cognition's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $59.61 Mil. Therefore, Alpha Cognition's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -43.47%.

The historical rank and industry rank for Alpha Cognition's Return-on-Tangible-Equity or its related term are showing as below:

ACOG' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -512.99   Med: -233.55   Max: -41
Current: -55.96

During the past 6 years, Alpha Cognition's highest Return-on-Tangible-Equity was -41.00%. The lowest was -512.99%. And the median was -233.55%.

ACOG's Return-on-Tangible-Equity is ranked worse than
57.65% of 1202 companies
in the Biotechnology industry
Industry Median: -42.435 vs ACOG: -55.96

Alpha Cognition  (NAS:ACOG) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Alpha Cognition Return-on-Tangible-Equity Related Terms


Alpha Cognition Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Alpha Cognition's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Cognition Return-on-Tangible-Equity Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial -512.99 -378.65 0.00 -88.44 -41.00

Alpha Cognition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.45 -116.71 -16.22 -57.34 -43.47

ACOG vs GNLX, VTVT, CRDF: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Alpha Cognition's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Cognition Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Cognition's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Alpha Cognition's Return-on-Tangible-Equity falls into.


ACOG
32GF Score
Alpha Cognition Inc ACOG
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Cognition Return-on-Tangible-Equity Calculation

Alpha Cognition's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-20.67/( (38.682+62.139 )/ 2 )
=-20.67/50.4105
=-41.00 %

Alpha Cognition's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-25.912/( (62.139+57.071)/ 2 )
=-25.912/59.605
=-43.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -43.47% mean?
Alpha Cognition (ACOG) has a Return-on-Tangible-Equity of -43.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alpha Cognition and its competitors. According to the industry distribution chart, Alpha Cognition ranks #693 out of 1202 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Alpha Cognition's Return-on-Tangible-Equity too high?
Alpha Cognition's current Return-on-Tangible-Equity is -43.47%. Based on the distribution chart, Alpha Cognition ranks #693 out of 1202 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Cognition has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Return-on-Tangible-Equity compare to GNLX and VTVT?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #693 out of 1202 companies for Return-on-Tangible-Equity. This places Alpha Cognition in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alpha Cognition and its competitors. Alpha Cognition's current Return-on-Tangible-Equity is -43.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Return-on-Tangible-Equity of -43.47%. The current Return-on-Tangible-Equity is -43.47%. Alpha Cognition's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Return-on-Tangible-Equity is -43.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Cognition Business Description

Other Exchanges 7N70:Germany
Address 1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
32GF Score

Get the complete analysis for ACOG

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.50
Price